OC METRO CALENDAR

  • April 2014
    SuMoTuWeThFrSa
    303112345
    6789101112
    13141516171819
    20212223242526
    27282930123
    45678910
Add an event

CONSTRUCTION INDUSTRY NEWS
Untitled Page

Irvine's LCS Constructors completes first phase of renovation project

Firm is revamping a 165,000-square-foot facility in Costa Mesa for Abraxis BioScience.

By Ashly McGlonePublished: April 27, 2010 02:08 PM

Irvine-based LCS Constructors has put the finishing touches on the first major phase of a renovation project for Abraxis BioScience's facility in Costa Mesa.

The 165,000-square-foot property was formerly occupied by ICN/Valient Pharmaceuticals and will serve as the site for Abraxis' research and development operations once the entire revamp is completed.

The biotechnology firm, which is relocating its research and development business from Marina del Rey, first hired LCS Constructors to evaluate the property, then signed the company on as the project's design-builder, after the study revealed a number of issues that need repair or retro-fitting.  

The first phase included significant seismic upgrades and renovating existing lab space, creating a new “state-of-the-art” laboratory for chemistry, biology, formulation and a biological safety lab.

“Although the team faced several unique challenges that accompanied these seismic upgrades, the team’s resourcefulness, combined with careful and deliberate planning, led to the successful completion of the first major phase of this project,” says Jim Koons, who is coordinating daily production of the renovation.

LCS Constructors was founded in 1980 and opened its first corporate office in 1991 in San Juan Capistrano. Management and field craftsmen at LCS Constructors have completed more than 3,000 lab projects.

Currently, the construction group is involved in projects for Cal Tech in Pasadena, ExxonMobil in Torrance and Plus Diagnostics in Irvine.

Abraxis, a biotechnology company based in Los Angeles, works to find new treatments for cancer and other pathological disorders.

The Abraxis portfolio includes the first and only protein-based nanoparticle chemotherapeutic compound.  

The next phase of the Abraxis project is pending.

Related headlines
The Arbor at Woodbury in Irvine lands Project of the Year award

Green apartment complex opens
Anaheim City Council OKs affordable housing plan